The effect of oral magnesium supplementation on acute non-specific low back pain: Prospective randomized clinical trial
Bayram S, Şahin K, Anarat FB, Chousein CM, Kocazeybek E, Altan M, Akgül T
The American journal of emergency medicine · 8 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2021-03-27 · Am J Emerg Med · vol. 47 · págs. 125–130
- Editorial
- Elsevier BV
- Citado
- 8 citas · más que el 62% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 27 trabajos
- Acceso
- De pago
- Áreas de investigación
- Musculoskeletal pain and rehabilitation · Magnesium in Health and Disease · Spine and Intervertebral Disc Pathology
- Palabras clave
- magnesium supplementation, acute low back pain, etodolac, paracetamol, nonsteroidal anti-inflammatory drugs, analgesic combination, lumbar spine mobility, functional outcome, pain intensity
- MeSH
- humans, low back pain, magnesium, anti-inflammatory agents, non-steroidal, drug therapy, combination, administration, oral, prospective studies, dietary supplements, adult, female, male
7 autores
- Serkan Bayram🇹🇷 · autor de correspondenciaIstanbul University
- Koray Şahin🇹🇷Istanbul University
- Fikret Berkan Anarat🇹🇷Istanbul University
- Chasan Memet Chousein🇹🇷Istanbul University
- Emre Kocazeybek🇹🇷Istanbul University
- Murat Altan🇹🇷Istanbul University
- Turgut Akgül🇹🇷Istanbul University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
We aimed to investigate the effect of oral magnesium supplementation for acute low back pain.
Methods
This is a three-arm, prospective randomized open label clinical trial, which included two hundred and forty patients. We based our sample size calculation assumptions on a recently published clinical trial, thus we enrolled 80 patients for each group. NSAID alone group included (400 mg etodolac twice a day), NSAID + mg group included NSAID - magnesium combination treatment (400 mg etodolac twice a day with 365 mg oral magnesium supplementation) and NSAID + paracetamol group included NSAID - paracetamol combination treatment (400 mg etodolac twice a day with 500 mg paracetamol twice a day). Follow-up visits after initiation of relevant treatment were performed at 4th and 10th days and outcome measures included pain (Visual analogue scale - VAS), mobility of lumbar spine and functional outcome (RMDQ).
Results
Thirty-one patients were considered lost to follow-up or excluded due to use of other medications and final analysis was performed with 209 participants in three groups (71 patients in NSAID alone group, 68 patients in NSAID + mg group and 70 patients in NSAID + paracetamol group). NSAID + mg showed a significantly higher improvement in RMDQ and VAS scores at acute stage (at 4th day visit) compared to two other study groups However, there was no significant difference between three groups in terms of mean improvement of RMDQ, VAS scores and lumbar mobility between initial visit and 10-day.
Conclusion
Results of this study suggest that addition of magnesium to acute low-back pain treatment does not significantly improve final clinical outcomes.
Level of evidence
Level I, prospective randomized controlled study.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.